Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Brepocitinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 known ✓ | P23458 | 20/20 | 1.00 |
| ▸ | TYK2 known ✓ | P29597 | 16/20 | 1.00 |
| ▸ | JAK2 | O60674 | 16/20 | 1.00 |
| ▸ | KDR | P35968 | 2/20 | 1.00 |
| ▸ | PRMT7 | Q9NVM4 | 1/20 | 1.00 |
| ▸ | JAK3 | P52333 | 5/20 | 0.82 |
| ▸ | STAT1 | P42224 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Brepocitinib SCHEMBL20767478 | 1.00 | JAK1 (1.00) | JAK1JAK2TYK2KDRPRMT7 | |
| Brepocitinib SCHEMBL17512520 | 0.91 | JAK1 (1.00) | JAK1JAK2TYK2KDRPRMT7 | |
| Brepocitinib SCHEMBL22345890 | 0.91 | JAK1 (1.00) | JAK1JAK2TYK2KDRPRMT7 | |
| Brepocitinib SCHEMBL17512502 | 0.91 | JAK1 (1.00) | JAK1JAK2TYK2KDRPRMT7 | |
| Brepocitinib SCHEMBL24172497 | 0.91 | JAK1 (1.00) | JAK1JAK2TYK2KDRPRMT7 | |
| Brepocitinib SCHEMBL24172557 | 0.91 | JAK1 (1.00) | JAK1JAK2TYK2KDRPRMT7 | |
| Brepocitinib SCHEMBL24293069 | 0.91 | JAK1 (1.00) | JAK1JAK2TYK2KDRPRMT7 | |
| Brepocitinib SCHEMBL24173034 | 0.91 | JAK1 (1.00) | JAK1JAK2TYK2KDRPRMT7 | |
| Brepocitinib SCHEMBL31291113 | 0.91 | JAK1 (1.00) | JAK1JAK2TYK2KDRPRMT7 | |
| SCHEMBL27018910 | 0.85 | JAK1 (0.90) | JAK1JAK2TYK2KDRPRMT7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4126874-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | Nuevolution A/S (DK) | 2023-02-08 | — | — | EP | claimed |
| EP-4126875-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | Nuevolution A/S (DK) | 2023-02-08 | — | — | EP | claimed |
| EP-4076657-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | Nuevolution A/S (DK) | 2022-10-26 | — | — | EP | claimed |
| EP-4076661-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | Nuevolution A/S (DK) | 2022-10-26 | — | — | EP | claimed |
| WO-2022161507-A1 | CRYSTAL FORM OF BREPOCITINIB TOSYLATE, AND PREPARATION METHOD AND USE THEREFOR | 杭州领业医药科技有限公司 | 2022-08-04 | — | — | WO | claimed |
| CN-114835717-A | Brepocitinib tosylate crystal form, preparation method and application thereof | 杭州领业医药科技有限公司 | 2022-08-02 | — | — | CN | claimed |
| EP-4687850-A1 | ORAL DRUG DOSAGE FORMS FOR COLON DELIVERY AND METHODS OF USE AND MAKING THEREOF | Triastek, Inc. (CN) | 2026-02-11 | — | — | EP | disclosed |
| US-12441704-B2 | Compounds active towards nuclear receptors | NUEVOLUTION A/S (DK) | 2025-10-14 | — | — | US | disclosed |
| WO-2024199448-A1 | ORAL DRUG DOSAGE FORMS FOR COLON DELIVERY AND METHODS OF USE AND MAKING THEREOF | Triastek, Inc. (CN) | 2024-10-03 | — | — | WO | disclosed |
| US-11780843-B2 | Compounds active towards nuclear receptors | NUEVOLUTION A/S (DK) | 2023-10-10 | — | — | US | disclosed |
| US-20230271937-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | NUEVOLUTION A/S (DK) | 2023-08-31 | — | — | US | disclosed |
| US-11685727-B2 | Compounds active towards nuclear receptors | NUEVOLUTION A/S (DK) | 2023-06-27 | — | — | US | disclosed |
| US-20230149407-A1 | Methods of Treating Coronavirus Disease 2019 | PFIZER INC. (US) | 2023-05-18 | — | — | US | disclosed |
| WO-2022161507-A1 | CRYSTAL FORM OF BREPOCITINIB TOSYLATE, AND PREPARATION METHOD AND USE THEREFOR | 杭州领业医药科技有限公司 | 2022-08-04 | — | — | WO | disclosed |
| WO-2022161507-A1 | CRYSTAL FORM OF BREPOCITINIB TOSYLATE, AND PREPARATION METHOD AND USE THEREFOR | 杭州领业医药科技有限公司 | 2022-08-04 | — | — | WO | disclosed |
| WO-2022161507-A1 | CRYSTAL FORM OF BREPOCITINIB TOSYLATE, AND PREPARATION METHOD AND USE THEREFOR | 杭州领业医药科技有限公司 | 2022-08-04 | — | — | WO | disclosed |
| CN-114835717-A | Brepocitinib tosylate crystal form, preparation method and application thereof | 杭州领业医药科技有限公司 | 2022-08-02 | — | — | CN | disclosed |
| CN-114835717-A | Brepocitinib tosylate crystal form, preparation method and application thereof | 杭州领业医药科技有限公司 | 2022-08-02 | — | — | CN | disclosed |
| CN-114835717-A | Brepocitinib tosylate crystal form, preparation method and application thereof | 杭州领业医药科技有限公司 | 2022-08-02 | — | — | CN | disclosed |
| US-20220098182-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | NUEVOLUTION A/S (DK) | 2022-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11780843-B2 | Compounds active towards nuclear receptors | NCOA1, NR1H2, NCOA3 | JAK1 4522/4885TYK2 3516/4885JAK2 3057/4885 |
| US-11685727-B2 | Compounds active towards nuclear receptors | NCOA1, NR1H2, NCOA3 | JAK1 4522/4885TYK2 3516/4885JAK2 3057/4885 |
| US-20220098182-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | NCOA1, NR1H2, NCOA3 | JAK1 4522/4885TYK2 3516/4885JAK2 3057/4885 |
| US-20230271937-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | NCOA1, NR1H2, NCOA3 | JAK1 4522/4885TYK2 3516/4885JAK2 3057/4885 |
| US-20230149407-A1 | Methods of Treating Coronavirus Disease 2019 | IRAK4, IRAK2, IRAK1 | JAK1 5/4885TYK2 6/4885JAK2 9/4885 |
| US-12441704-B2 | Compounds active towards nuclear receptors | NCOA1, NR1H2, NCOA3 | JAK1 4522/4885TYK2 3516/4885JAK2 3057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.